Research synthesisLow evidenceSmall effect3 studies · 1 beneficial · 2 neutral · 0 harmful
Across 3 studies, 1 reported a beneficial small-sized effect on reducing interleukin-6 levels, while 2 found neutral effects (no significant reduction). The sole beneficial study was a large meta-analysis in older adults with sarcopenia (n=1154), which reported a significant small effect. The median study duration was 56 days (based on 1 study), though limited duration data prevents strong conclusions about timing. The most studied population was clinical (sarcopenia, frailty, hemodialysis patients).
- Studied populations: older adults with sarcopenia, hemodialysis patients, individuals with sarcopenia and pre-frailty
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Only one study reached statistical significance; the two neutral studies did not find a significant IL-6 reduction, so the effect may be inconsistent or limited to specific populations. The beneficial effect was observed in a meta-analysis of sarcopenic older adults; it is unclear whether the same benefit extends to other groups.
Generated Jun 11, 2026